Associated Papers
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
Yang G et al.
Discover Oncology, 2024
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
Pahuja KB et al.
Cancer Cell, 2018
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
Ou SI et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2017
HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy.
Notsuda H et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2017
Select a paper to view details